COVID-19 Funding Opportunities

I.) National Institutes of Health (NIH)

Notice of Special Interest (NOSI) on Pan-Coronavirus Vaccine Development Program Projects
NIAID is issuing this Notice of Special Interest (NOSI) to highlight the critical need to develop prophylactic vaccines able to provide broad and durable protection against coronaviruses (CoVs), especially SARS-CoV-2 and others with pandemic potential. NIAID is particularly interested in highly collaborative, multi-disciplinary Program Projects (P01s) that incorporate understanding of CoV virology and immunology, immunogen design, and innovative vaccine and adjuvant platforms and technologies to discover, design, and develop pan-coronavirus (pan-CoV) vaccine candidates that provide broad protective immunity to multiple CoV strains.

Deadline: January 11, 2021

National Institute of General Medical Sciences (NIGMS)
Predictive models for the spread of SARS-CoV-2 and other related infectious agents (all relevant grants). Repurposing or modification of diagnostic tools currently under development to enable rapid detection of SARS-CoV-2 infection; rapid development of potential therapeutic agents for COVID-19 (SBIR/STTR grants only).

Deadline: Rolling through February 6, 2021

Digital Healthcare Interventions to Address the Secondary Health Effects Related to Social, Behavioral, and Economic Impact of COVID-19 (R01 - Clinical Trial Optional)
This FOA aims to support research to strengthen the healthcare response to Coronavirus Disease 2019 (COVID-19) caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and future public health emergencies, including pandemics. The purpose of this funding opportunity is to focus on the role and impact of digital health interventions to address access, reach, delivery, effectiveness, scalability and sustainability of health assessments and interventions for secondary effects that are utilized during and following the pandemic, particularly in populations who experience health disparities and vulnerable populations.

Deadline: March 2, 2021

National Institute of Allergy and Infectious Diseases (NIAID) - NOSI: Emergency Competitive Revisions for Research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19)
Viral natural history, pathogenicity, transmission, as well as projects developing medical countermeasures and suitable animal models for pre-clinical testing of vaccines and therapeutics against SARS-CoV-2/COVID-19.

Deadline: Rolling through March 25, 2021

National Institute of Drug Abuse (NIDA)
Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements and Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus. NIDA is interested in research collecting and examining data on the risks and outcomes for COVID-19 infection in individuals suffering from substance use disorders.

Deadline: Rolling, through March 31, 2021

National Institute of Allergy and Infectious Diseases (NIAID) - Emergency Awards: Rapid Investigation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19)
The purpose of this Funding Opportunity Announcement (FOA) is to provide an expedited funding mechanism for research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19). NIAID is issuing this FOA in response to the declared public health emergency issued by the Secretary, HHS, for 2019 Novel Coronavirus (COVID-19).

Deadline: Rolling, through April 30, 2021
COVID-19 Funding Opportunities

Emergency Awards: Notice of Special Interest (NOSI) on Pan-Coronavirus Vaccine Development Program Projects
NIAID has issued a Notice of Special Interest (NOSI) to highlight the critical need to develop prophylactic vaccines that are able to provide broad and durable protection against coronaviruses (CoVs), especially SARS-CoV-2 and others with pandemic potential. NIAID is particularly interested in highly collaborative, multi-disciplinary Program Projects (P01s) that incorporate understanding of CoV virology and immunology, immunogen design, and innovative vaccine and adjuvant platforms and technologies to discover, design, and develop pan-coronavirus (pan-CoV) vaccine candidates that provide broad protective immunity to multiple CoV strains.

**Deadline: June 11, 2021**

II. Other US Funding Agencies

ADB Digital – COVID-19 Vaccine: Safety and Immunization Monitoring
The Asian Development Bank has launched a series of challenges calling for digital health solutions to help achieve successful vaccination programs in the developing countries that it serves. The first of these is related to the development of digital tools for vaccine safety and immunization monitoring. The Challenge includes Application, Evaluation, Mentoring, and Pitching phases, culminating in selection of the winning solution by a panel of experts.

Topics: Proposed solutions should address the following areas:
- Providing the general population with accurate and timely information about accredited COVID-19 vaccine administration sites
- Setting clear expectations about common side effects following vaccination
- Actively monitoring mild and potentially more serious side effects post-vaccination
- Sending reminders for the second dose (if needed depending on vaccine type).
- Clearly addressing potential concerns related to COVID-19 vaccine safety and hesitancy
- Educating the public about the benefits of COVID-19 vaccination to increase public confidence

**Due Date: January 31, 2021**

ADB Digital – COVID-19 Vaccine: Safety and Immunization Monitoring
The ADB’s second challenge addresses the tracking of administered vaccines in the bank’s developing member countries. The challenge calls for digital health solutions to support large, complex vaccination programs involving two-dose COVID-19 vaccines.

Topics: Proposed solutions should address the following areas:
- Informing people about what vaccine they are getting and reminding them to get the second vaccination
- Assisting health care providers with tracking of who has received which vaccine so that they can provide the correct second dose
- Supporting governments in distributing the right type of vaccine to the right geographic regions within the country to avoid stock-out, especially when people are ready for the second dose

**Due Date: January 31, 2021**

Fast Grants
Fast grants are available exclusively to PIs at academic institutions already working on COVID-19 related projects that could help with the pandemic within the next six months.

**Due Date: Rolling, award decisions made in 48 hours**
COVID-19 Funding Opportunities

**Wellcome, Bill & Melinda Gates Foundation, and Mastercard**
The Bill & Melinda Gates Foundation, Wellcome, and Mastercard have committed up to $125 million in seed funding to speed-up the response to the COVID-19 epidemic by identifying, assessing, developing, and scaling-up treatments. The Accelerator is seeking partners for the following activities:
• Identifying candidate compounds by testing approved drugs for activity against COVID-19, screening libraries of compounds with confirmed safety data, and considering new investigational compounds and monoclonal antibodies.
• Developing drugs or monoclonal antibodies that pass initial screening.
• Scaling up production and commercialization of successful drugs and monoclonal antibodies.

**Deadline: Not Specified**